Fennec Pharmaceuticals Inc is making waves on the TSX with a significant price surge.
Fennec Pharmaceuticals Inc (FRX.TO) is up today, showing a solid increase of 7.44% in its stock price. This rise has caught the attention of investors looking for promising opportunities in the biotech sector.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$484.58M
52W high
$15.48
52W low
$7.59
1W change
-0.72%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 575.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+575.6% Upside
Current Price
C$13.85
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
48.5%
Annualized
90-Day Vol
82.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.70 | C$12.44 – C$17.37 |
| 60 trading days | C$15.60 | C$12.32 – C$19.76 |
| 90 trading days | C$16.56 | C$12.39 – C$22.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The stock's recent performance highlights Fennec's potential for growth, especially as it continues to innovate in the pharmaceutical space.
Fennec Pharmaceuticals Inc's stock price is CA$14.88
With a market cap of CA$484.58 million, Fennec's stock movement reflects growing investor confidence.
Bull case
Investors are feeling positive about Fennec's ongoing developments and the potential in the market, especially with its flagship product, PEDMARK®, which is gaining traction.
Bear case
Despite today's gains, Fennec Pharmaceuticals still faces challenges, such as a lack of profitability and competition in the biotech industry.
Advertisement
Market Performance Overview
Fennec Pharmaceuticals Inc's stock is rising today, currently priced at CA$14.88. The 7.44% increase signals a positive shift in investor sentiment, likely driven by recent developments in the company's product pipeline and market strategies.
Investor Sentiment and Future Outlook
The recent surge in Fennec's stock price reflects growing confidence among investors about the company's future. With ongoing research and development efforts, particularly around PEDMARK®, there is potential for continued growth, despite existing challenges in profitability and competition.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
